Medicare may save $1.8B from four drugs in first year of price negotiations, research finds
A new paper published this week claims that in 2026, when Medicare negotiations for drug prices kick off, the minimum discount stipulated by the Inflation Reduction Act exceeds 2020 rebates for only four of the 10 drugs to be negotiated.
On Sept. 1, CMS is expected to announce those 10 drugs first subject to government price negotiations.
“These include etanercept (Enbrel), which will be subject to at least a 60% discount, up from an estimated rebate of 39.1%, and the cancer drugs ibrutinib (Imbruvica), palbociclib (Ibrance), and enzalutamide (Xtandi), all of which will be subject to a minimum discount of 25%, up from estimated rebates of 9%, 5.7%, and 15.0%, respectively,” researchers from the University of California, San Diego and Washington, DC’s West Health Policy Center wrote in the Journal of Managed Care & Specialty Pharmacy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
